CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News CytoDyn is  a   biotech which has been effective conscientiously but unsuccessfully to produce an one-time therapy, variously named Pro 140, leronlimab, as well as Vyrologix. In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases of potential […]

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective conscientiously but unsuccessfully to produce an one-time therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn's inventories of leronlimab are building up, whether they'll actually be used is actually an open question.


While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV happen to be closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the last several shares of mine. The first CytoDyn post of mine, "CytoDyn: What to be able to Do When It's Too Good To Be True?", set out the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very promotional picture in the Uptick Newswire job interview that I came away with a poor opinion of the company.

Irony of irony, the bad opinion of mine of the business has grown steadily, however, the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc.... has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the treatment as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today's transaction of $3.5 huge number of transfers ownership of this expertise as well as linked intellectual property coming from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance.... milestone payments after commencement of a stage III clinical trial ($1.5 huge number of) plus the very first new drug application endorsement ($five million), and even royalty payments of five percent of net sales after commercialization.

Since that point in time, CytoDyn's helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and numerous indications, it's this single therapies in addition to a "broad pipeline of indications" as it places it. I call certain pipelines, "pipedots." In CytoDyn's case it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

Its opening banner on its site (below) shows an energetic company with diverse interests albeit centered on leronlimab, several disease sorts, multiple delivering presentations and multiple publications.

Can all of it be smoke cigarettes and mirrors? That's a question I've been asking myself through the really start of my interest in this particular organization. Judging by the multiples of a huge number of several responses on listings accessible through Seeking Alpha's CytoDyn Summary webpage, I am much from alone in this particular question.

CytoDyn is a traditional battleground, or maybe some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *